Data from: Prognostic significance of serum albumin in patients with stable coronary artery disease treated by percutaneous coronary intervention

Background: Stable coronary artery disease (CAD) is known to have an
increased risk of cardiovascular events. Serum albumin (Alb) is reported
as a useful risk-stratification tool in cardiovascular diseases such as
acute coronary syndrome or heart failure. However, the association between
Alb and stable CAD is unclear. Thus, we aimed to investigate the
prognostic significance of Alb in patients with stable CAD. Methods and
results: We analyzed the data of all patients admitted to Shinonoi General
Hospital between October 2014 and October 2017 for newly diagnosed stable
CAD, treated via elective percutaneous coronary intervention, with the
exception of old myocardial infarction. We collected data, including Alb,
at admission. The primary endpoint was major adverse cardiac events (MACE;
defined as all-cause death, non-fatal myocardial infarction, non-fatal
stroke). In 204 enrolled patients (median age, 73 years), during a median
follow-up of 783 days, 28 experienced MACE. Alb was significantly lower in
patients with MACE than in those without (p<0.001). In Kaplan-Meier
analysis, low Alb predicted worse prognosis in MACE (p<0.001). In
multivariate Cox regression analysis, low Alb levels independently
predicted MACE (p<0.001) after adjusting for age and sex (HR 4.128
[95% CI 1.632–10.440], p = 0.003), or, age and C-reactive protein (HR
3.373 [95% CI 1.289–8.828], p = 0.013). Conclusions: Low Alb levels
predicted MACE in patients with stable CAD.